6.35
전일 마감가:
$6.558
열려 있는:
$6.36
하루 거래량:
1,275
Relative Volume:
0.05
시가총액:
$7.44M
수익:
-
순이익/손실:
$-57.11M
주가수익비율:
-0.4233
EPS:
-15
순현금흐름:
$-34.82M
1주 성능:
-4.28%
1개월 성능:
+4.10%
6개월 성능:
-34.87%
1년 성능:
-69.76%
아폴로믹스 Stock (APLM) Company Profile
APLM을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
APLM
Apollomics Inc
|
6.455 | 7.44M | 0 | -57.11M | -34.82M | -15.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
454.53 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
544.28 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.82 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
557.13 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.13 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
아폴로믹스 주식(APLM)의 최신 뉴스
New Age Metals (OTCMKTS:NMTLF) Trading 1.2% Higher – Here’s Why - Defense World
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 87.9% - Defense World
Orca Energy Group (OTCMKTS:ORXGF) Trading 1.4% Higher – What’s Next? - Defense World
(APLM) Long Term Investment Analysis - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Increases By 75.8% - Defense World
How the (APLM) price action is used to our Advantage - news.stocktradersdaily.com
Apollomics (APLM) Trading Halted Due to Volatility | APLM Stock News - GuruFocus
Apollomics (APLM) Stock Trading Resumes | APLM Stock News - GuruFocus
(APLM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Short Interest in Apollomics, Inc. (NASDAQ:APLMW) Decreases By 44.4% - Defense World
APLM stock touches 52-week low at $4.71 amid sharp annual decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $4.71 amid sharp annual decline - Investing.com Canada
(APLM) Investment Analysis - news.stocktradersdaily.com
APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times
Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan
Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia
Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire
$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - marketscreener.com
Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail
Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World
These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail
(APLM) Trading Advice - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa
GlycoMimetics ends key agreement; board members, executives depart - Investing.com
APLM stock touches 52-week low at $6.38 amid market challenges - MSN
APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa
Objective long/short (APLM) Report - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics, after giving up on GlycoMimetics' leukemia therapy, posts drug's latest phase 3 fail - Fierce Biotech
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - GlobeNewswire
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - Marketscreener.com
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 - Yahoo Finance
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Apollomics Inc.: Directors (Cayman Islands, 2024) - OffshoreAlert
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewswire
Apollomics Announces Positive Preliminary Data of - GlobeNewswire
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference - Yahoo Finance
아폴로믹스 (APLM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):